Lavinia Iordache

Lavinia Iordache practices at Sylvester Comprehensive Cancer Center in Miami, Florida, part of University of Miami.

Lavinia Iordache's NPI, 1770961203, was assigned on May 17, 2015. Lavinia Iordache holds Florida license PA9108588.

Lavinia Iordache's primary practice is Sylvester Comprehensive Cancer Center, at 1475 Nw 12th Ave, Miami, FL 33136.

Lavinia Iordache's primary practice is Sylvester Comprehensive Cancer Center in Miami, Florida, part of University of Miami. The medical group on file is University of Miami Health System. Dmand AI also links Lavinia Iordache to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Lavinia Iordache practices, 2 sites in all. Vendor and product names are available with a free account.

Physician assistant is Lavinia Iordache's primary specialty in the NPI Registry, under taxonomy code 363A00000X. Lavinia Iordache is board certified in certified physician assistant by the National Commission on Certification of Physician Assistants (NCCPA). Lavinia Iordache is licensed in Florida.

Dmand AI lists hemorrhoids and vitamin d deficiency among the conditions Lavinia Iordache treats.

CMS data shows 246 Medicare services from Lavinia Iordache across 4 procedure codes in 2024, for 178 Medicare patients. Medicare paid $18,489 for them.

CMS counts 178 Medicare patients who saw Lavinia Iordache in 2024. The largest group is 65 to 74, with 93 patients. 75% of them have high cholesterol, and 74% have high blood pressure. 33% are also on Medicaid. Their average risk score is 2.21, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Lavinia Iordache's median patient age at 64, with 62% women.

In 2024, Lavinia Iordache wrote 588 Medicare Part D claims for 113 patients. 77% of them were for generic drugs. CMS names the drug for 465 of them, across 17 drugs with 11 or more claims each, at $202,373 in total drug cost.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Lavinia Iordache for performance year 2024, reported as part of a group. Lavinia Iordache accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Lavinia Iordache as offering telehealth.

CMS Open Payments shows 38 general payments to Lavinia Iordache from 8 drug and device companies from 2024 to 2025. Speaker and faculty fees make up the largest share, 57% of the total. Madrigal Pharmaceuticals paid the most, $3,193.